Get started
Novo Nordisk A/S Class BNovo Nordisk A/S Class BNovo Nordisk A/S Class B

Novo Nordisk A/S Class B

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Trade ideas

Time to go Long NVO?NVO has had a tough year. It's down 53% ytd. I accumulated 100 shares at $50 in August and stupidly held the bag despite the price hitting my target of 60. The price is back down around $50, and looking like a good time to buy. If you look down at the RSI the last 2 times it sunk to oversold, it triggered runs of 10-20pts. Personally, I think the stories of increased competition are overblown. This is the largest company in Europe and still a leader. The share price needs help from some US gov't policy, but it's definitely in its accumulation zone again. Moreover, it looks like it could finally break the downward trendline started back in December. Share prices dopped to $50 once again today on the news that it's bidding on Metsera. And on the news, I bought another 100 shares. This trade is active.
NYSE:NVOLong
by brendanvanson
$NVO Novo Nordisk | pump or PAMP?!?!X is abuzz with musical PAMP chairs these days. It's like a meme merry-go-round. Because nothing says "fun" like a game where everyone's pumping stocks until the music stops and you're left holding the bag of sadness. NYSE:NVO is popping up more and more in the chatter. Thought we'd take a look to see what we see. $40 looks like a reasonable ( as reasonable as an extended weather forecast ) price target. There seems to be this repeating pattern of dump, upwards consolidation, dump, upwards consolidations, AND REPEAT. I like to front-run so, I'm already in. Will add around $40ish. SEE U ON THE MOON!
NYSE:NVOLong
by MonsterStockPicks
2
NVO-Hold or cut lossIt has been quite a crappy month for this stonk. But if this pull back(if it is turn out to be a pull back) can hold firm support at fib 0.78 level at around $48. Then we can still expect a reversal to the upside to be play out. But is we loose this or previous low then we will probably see another lower low. With current undervaluation of this stock, with bullish weekly bullish divergent still intact, I believe we are more like to make a reversal to the upside from here
NYSE:NVO
by JustBuyAndPrayToTheChart
$NVO Short Setup | EMA Wall Stops Bulls, Downside Active🎯 NVO Bearish Breakdown: 200 EMA Rejection Setup 🐻 📊 Asset Overview Novo Nordisk (NVO) - NYSE Type: Swing/Day Trade Opportunity Bias: Bearish Reversal Confirmed ⚠️ 🔍 Technical Analysis The bulls just got rejected harder than a bad pickup line at the 200 EMA! 📉 We're seeing strong bearish momentum building up with heavy downside pressure taking control. The market structure screams reversal, and bears are flexing their dominance. Key Technical Factors: 🚫 200 Exponential Moving Average acting as dynamic resistance 📉 Bearish momentum accelerating with high selling pressure 🔄 Clear market structure reversal pattern forming 🐻 Bears in full control of price action 💰 Trade Setup - "The Thief Strategy" 🎯 Entry Strategy Layering Method - Multiple limit orders for optimal positioning: Layer 1: $53.00 Layer 2: $52.00 Layer 3: $51.00 Feel free to add more layers based on your risk appetite and account size! 🛑 Stop Loss Thief SL: $56.00 ⚠️ Risk Disclaimer: This is MY stop loss level. You're the captain of your own ship - adjust based on your risk tolerance and trading plan. Trade at your own risk! 🎯 Target Zone Primary Target: $44.00 📍 Why $44? Strong support confluence + oversold conditions + potential bull trap zone. Smart money takes profits where the crowd panics! ⚠️ Profit Taking Note: This is MY target. You make your money, you take your money. Don't be greedy - secure those gains when YOUR plan says so! 🔗 Related Pairs to Watch Keep your eyes on these correlated assets for confirmation: 📈 Pharma/Healthcare Sector: NYSE:LLY (Eli Lilly) - Direct competitor in diabetes/obesity space NASDAQ:SNY (Sanofi) - European pharma correlation AMEX:XLV (Healthcare ETF) - Sector-wide momentum gauge 💵 Currency Impact: TVC:DXY (US Dollar Index) - Strong dollar = pressure on international stocks $EUR/USD - Danish Krone correlation (Denmark-based company) 💊 Related Healthcare Plays: NYSE:JNJ (Johnson & Johnson) - Large-cap healthcare sentiment NYSE:PFE (Pfizer) - Big pharma correlation Watch for divergences or confirmations across these pairs to validate the bearish thesis! 📝 Key Points Summary ✅ 200 EMA rejection = institutional selling zone ✅ Bearish market structure confirmed ✅ Multiple entry layers = better average price ✅ Strong support target at $44 = ideal exit zone ✅ Risk management is KING 👑 ⚡ The Thief's Edge This "layering strategy" lets you build positions gradually while managing risk like a pro. Instead of going all-in at one price, you spread your entries to capture the best average. It's not about timing the perfect entry - it's about stacking the odds in your favor! 🎲 🎭 The Thief Strategy: A playful nickname for layered limit order entries. Trade responsibly and within your means. ✨ If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community! #NVO #NovoNordisk #BearishSetup #SwingTrading #DayTrading #TechnicalAnalysis #StockMarket #NYSE #ThiefStrategy #LayeringStrategy #PharmaStocks #200EMA #BearishReversal #TradingIdeas #PriceAction #RiskManagement #Healthcare #BiopharmaTrade
NYSE:NVOShort
by The-Thief
Novo Nordisk Setup – Is This the Pharma Sector’s Strongest Play?🚀 NVO "Novo Nordisk" – Wealth Strategy Map (Swing/Day Trade) 📈 Trade Plan (Bullish Setup) Trend Confirmation: The bullish trend is supported by Dow Theory accumulation phase 📊. Candle Signal: A Heikin Ashi Doji has formed, adding confluence to the setup. Indicator Alert: LSMA (Least Squares Moving Average) line has confirmed a breakout, reinforcing the bullish case. 🎯 Entry Strategy (Layering Style) This plan uses a layered entry approach — placing multiple buy-limit orders across price levels to scale into the trade: Layered Buys: 54.00 → 55.00 → 56.00 → 57.00 (⚡ You can expand your limit layers further depending on your own preference and risk appetite.) ✅ This layered method allows flexibility, smoothing entries instead of relying on a single price level. 🛡️ Risk Management Stop Loss Idea: Suggested protective stop near 52.00 🔒. 📢 Note: Risk is personal! Adjust your SL to fit your risk tolerance, capital, and trading style. 🎯 Profit Target Target Zone: 66.00 (area of heavy resistance + possible overbought levels ⚡). ⚠️ Note: Exiting before the “crowd trap” forms is key — take profits wisely when conditions match your own plan. 🔗 Related Pairs to Watch NYSE:NVO (Primary) NYSE:LLY (Eli Lilly) 🧬 – Correlated pharma sector, often mirrors biotech sentiment. SP:SPX / AMEX:SPY 📊 – Broader market direction can impact large-cap pharma momentum. $USD/SEK 💱 – Novo Nordisk is Danish; currency fluctuations sometimes influence investor flow. Keeping an eye on these correlated assets can improve timing and risk management. ✨ “If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community!” #NVO #NovoNordisk #Stocks #SwingTrade #DayTrade #StockMarket #Bullish #HeikinAshi #DowTheory #TradingStrategy #PharmaStocks #LayeredEntries #RiskManagement
NYSE:NVOLong
by The-Thief
$NVO – Completed Supercycle, ABC Correction Underway (Monthly)www.tradingview.com Redrew the long-term channel to fit the entire price history — and every major swing since the 1980s now aligns perfectly within it. Within this structure, NYSE:NVO appears to have completed a clear 5-wave advance (1987–2023). The impulsive phase looks mature, and the price action since the 2023 top suggests the start of a larger-degree ABC correction. At present, price action fits the profile of the A-leg — strong downside momentum, deep RSI reset, and first break below the EMA100. I expect a B-wave retrace to test resistance near the channel midline or EMA, followed by a C-wave completing lower within the channel. This would mark the first true multi-year correction of Novo’s 40-year supercycle.
NYSE:NVO
by tex071173952
4
Novo Nordisk – 40-Year Supercycle Breakdown (Monthly)After nearly four decades inside a rising secular channel, Novo Nordisk broke below it for the first time ever in July 2025 . Since then, two consecutive monthly closes below the channel — coupled with two consecutive closes under the monthly EMA 100 (previously flawless support) — confirm a major structural shift . The failure of bulls to reclaim either the EMA 100 or the channel underscores that bears are now firmly in control . From an Elliott Wave perspective, price action since 1987 forms a clear completed 5-wave super-cycle , suggesting a larger-degree corrective phase is underway. A move toward ±$25 — aligning with the 23.6 % Fibonacci retracement of the entire advance — stands out as a primary downside target . Even this level would represent only a shallow retracement of the full trend, implying that the current decline may still be in its early stages.
NYSE:NVOShort
by tex071173952
14
$NVO end of bearish trend. - NYSE:NVO has exited the bearish trend and very soon it will be doing a trend reversal and enter a new trend. - if it consolidates, trade sideways or up is yet to be seen. - However, if a stock exits such a prominent downtrend then move to the upside after breakout is explosive. - Fundamentals are backing $NVO. - R&D is crown jewel of this company - Operation efficiency is improving under the new leadership - Entering new markets like India would unlock huge market for NYSE:NVO - Pills are the next growth lever for the company. - On top of that, Valuation is too cheap for an exploding TAM of weight loss and it's health benefit.
NYSE:NVOLong
by bigbull037
Is Novo breaking out of a falling trend channel?In 2024, Novo formed a head–shoulder pattern with a breakdown at the end of September. Since then, the stock has been moving within a falling trend channel until now. On September 18 this year, the stock broke above the trend channel by 6–7% on increased volume. It has since pulled back to test the upper line of the channel and is now moving up again. There is resistance around 390. If the stock breaks significantly above this level with rising volume, it will be clearly technically positive. Price momentum indicators are currently neutral, and the stock remains within a red Ichimoku cloud, but RSI 21 is trending higher. The stock is slightly technically positive at this point but could quickly turn decisively positive if it breaks above 390. The analysis covers a medium-term horizon (1–6 months). Fundamentals: Fundamental analysts remain broadly positive on the stock. “Novo announced a global restructuring affecting 9,000 employees. The purpose is to increase decision-making speed, strengthen performance culture, and redirect resources toward growth areas within diabetes and obesity ... Despite short-term uncertainty, we assess that growth potential remains attractive (though somewhat lower than previously expected). The pipeline is strong, and Novo remains in a leading capacity position.” Quoted from Jyske Bank, Denmark. Disclaimer: I hold a position in the stock. Note: You must do your own research and assessment before buying or selling shares.
OMXCOP:NOVO_B
by scorpiris
3
NVO: Awakening a Sleeping GiantNovo Nordisk (NVO) has been through a turbulent period marked by political pressure, leadership transition, and volatile price action. Once a dominant growth leader, the stock entered a prolonged downtrend, losing nearly two-thirds of its value from its highs. But beneath the surface, critical structural shifts are forming. The following stages will outline the necessary phases that must develop for this turnaround to materialize—from breaking free of long-term downtrends, to establishing structural reversal patterns, to executing a clean breakout that reawakens this sleeping giant. Combined with improving sentiment, attractive valuations, and new product catalysts, NVO presents one of the most important turnaround stories in the market today. Phase 1: The Big Picture – The End of the Downtrend On the higher timeframe, NVO has been trapped in a descending channel and falling wedge pattern. Each rally attempt failed against the channel’s upper trendline, while successive lower lows (LLs) reinforced bearish momentum. However, the most recent action has shown resilience: Price defended the $44–$45 critical low with volume spikes that suggest institutional accumulation. The falling wedge structure, a classic reversal pattern, is nearing its breakout point. Key resistance sits at $71–$74, where a confirmed break would mark the first structural higher high since the decline began. The macro picture suggests the downtrend is losing steam. The sleeping giant is stirring. Phase 2: The Reversal Zone – Foundation Building Zooming into the mid-timeframe charts, NVO has already laid the early foundations of reversal: A double bottom (DB) structure formed at the lows, rejecting heavy selling pressure. Break of structure (BoS) moves show that sellers are no longer fully in control. Higher lows (HLs) are emerging, indicating the gradual handoff from distribution to accumulation. Importantly, this structural base coincided with a major August catalyst: Novo Nordisk’s U.S. approval for a treatment of MASH. While initial headlines around price controls and leadership change spooked markets, the regulatory win highlights the company’s ability to expand beyond GLP-1 dominance and diversify revenue streams. The $71 level becomes the pivot. A break and retest above it confirms the foundation and sets the path forward. Phase 3: The Execution – Unlocking the Breakout Price action on the execution timeframe is coiled inside a descending triangle that aligns with the larger falling-wedge setup. Price has reclaimed the $59–$62 base and is pressing toward the $71–$74 neckline. What must happen next: Break and close above $71–$74 to confirm the reversal. Retest/hold $71 as support**;** shallow pullbacks with higher lows are ideal. Expand toward $80–$82 (first measured objective). If momentum persists, $95–$100 becomes the next leg as longer MAs are approached. Volume is the tell! A capitulation spike marked the late-July/early-August low—classic washout behavior. Subsequent rallies show rising participation, while pullbacks have occurred on contracting volume—an accumulation signature. On the breakout through $71–$74, look for clear volume expansion versus recent sessions to validate the move. The volume profile shows a high-volume node around $59–$62 (firm base) and a lower-volume pocket from ~$71 to low-$80s—price often moves faster through low-volume areas once acceptance is established. Invalidation A heavy-volume rejection at $71–$74 or loss of $59–$62 would negate the immediate setup and put a retest of the mid-50s back on the table. Net: execution now hinges on a high-participation break and hold above $71–$74; volume confirmation is the key to unlocking the next leg higher. Macro & Valuation Context Beyond the technicals, the macro story matters. August’s turbulence was driven by political rhetoric on drug pricing and leadership transitions, both of which suppressed sentiment. Yet underneath: Product diversification: Wegovy continues to expand, with new approvals boosting demand. The MASH approval signals expansion into adjacent therapeutic markets. Earnings strength: Despite headwinds, Novo Nordisk continues to deliver double-digit sales growth in core franchises. Valuation reset: After the drawdown, NVO trades at a far more reasonable P/E multiple compared to its stretched valuations at $140+. While still premium to peers, the multiple now reflects normalized expectations and leaves room for upside if earnings deliver. In short: the giant is cheaper, leaner, and ready to awaken. Conclusion: The Beautiful Awakening NVO’s charts tell a story of capitulation, base building, and now the early signs of reversal. From the high-timeframe falling wedge, to the mid-level double bottom and higher lows, to the execution-level triangle breakout—the technicals are aligned. Paired with a valuation reset and expanding product catalysts, Novo Nordisk is no longer a fading leader. It is a sleeping giant at the edge of awakening. For traders, the roadmap is clear: confirmation above $71 unlocks higher targets. For investors, the opportunity lies in recognizing that giants don’t sleep forever—they eventually rise again.
NYSE:NVOLong
by oneforthestacks
8
$NVO supertrend 3-5x in next 5 years- Don't trade NYSE:NVO but invest. - NYSE:NVO is in 28 years of uptrend and the innovation DNA of this company will prove the investors yet again. - Reasons to be bullish on NYSE:NVO - NYSE:NVO is making pills for weightloss but that not only helps in weight management but also reduces risk of heart attack, stroke, control diabetes. - Injections are costly to manufacture and has less shelf life on top of that in order to take injections one often require assistance whereas pills is very easy to consume just like vitamins. - NYSE:NVO move towards oral pills unlock massive TAM ( technical addressable market ) as millions of people are suffering with obesity, diabetes, chronic heart and brain disease that having access to this pill would be like getting a vitamin pill. - NYSE:NVO is like index fund for denmark just like NASDAQ:QQQ where majority of weight is taken by big tech stocks. Danish funds and people will continue to buy the dip regardless of whether NYSE:NVO is in bearish cycle or bullish. - NYSE:NVO valuation is super cheap and is even lower than NYSE:NVO started the injectibles for weight loss. - NYSE:NVO leadership is reflective and has conducted reduction in workforce which is rare for healthcare company as healthcare company usually run like welfare/government bloated. CEO is ready to keep startup like culture and promote innovation DNA alive. - I believe NYSE:NVO offers asymmetric opportunity and is going to be a long term compounder for years to come.
NYSE:NVOLong
by bigbull037
1
Why Did Novo Stock Fall So Sharply YesterdayNovo Nordisk shares plunged nearly 20–23% on July 29, 2025, marking its worst trading day since Black Monday in 1987. Significant Downgrade of 2025 Financial Outlook The company revised its sales growth forecast for 2025 down to 8–14%, from its prior guidance of 13–21%, and reduced expected operating profit growth from 16–24% to 10–16%. This adjustment was attributed to weaker-than-expected demand for Wegovy and Ozempic, and rising competitive pressures #TheWallStreetJournal I will start my accumulation using DCA, but will be happier to start buying this stock heavily from $47 zone. trade with care. I look forward to connecting with you
NYSE:NVOLong
by ForexClinik
1